Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| Bath'i anküloseeriva spondüliidi funktsionaalne indeks (BASFI)× | Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)× | |
|---|---|---|
| Valdkond | Reumatoloogia | Reumatoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 1994 | 2002 |
| Looja≠ | Calin et al. | Gladman et al. |
| Tüüp≠ | Patient-reported outcome (PRO) | Clinician-rated |
| Algallikas≠ | Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology. 1994;21(12):2281-2285. link ↗ | Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291. link ↗ |
| Rööpnimetused≠ | BASFI, BAS-FI | SLEDAI, SLEDAI-2K, SLE Disease Activity Index |
| Seotud≠ | 4 | 3 |
| Kokkuvõte≠ | The BASFI is a patient-reported outcome measure of functional disability in ankylosing spondylitis (AS), assessing physical limitations in 10 common daily activities. Introduced by Calin et al. in 1994, BASFI measures the impact of AS on quality of life and functional capacity, complementing BASDAI (disease activity). While BASDAI reflects inflammatory burden, BASFI reflects the consequences of inflammation and spinal damage on a patient's ability to perform daily tasks. BASFI is used alongside BASDAI in AS management to capture both disease activity and its functional impact. | The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease. |
| ScholarGateAndmestik ↗ |
|
|